(NASDAQ: ADMA) Adma Biologics's forecast annual revenue growth rate of 22.9% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 50.27%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.79%.
Adma Biologics's revenue in 2025 is $382,808,677.On average, 1 Wall Street analysts forecast ADMA's revenue for 2025 to be $112,356,287,251, with the lowest ADMA revenue forecast at $112,356,287,251, and the highest ADMA revenue forecast at $112,356,287,251. On average, 1 Wall Street analysts forecast ADMA's revenue for 2026 to be $138,761,078,511, with the lowest ADMA revenue forecast at $138,761,078,511, and the highest ADMA revenue forecast at $138,761,078,511.
In 2027, ADMA is forecast to generate $168,569,889,414 in revenue, with the lowest revenue forecast at $168,569,889,414 and the highest revenue forecast at $168,569,889,414.